950210 — Prestige Biopharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapMomentum Trap

Annual cashflow statement for Prestige Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

	2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-12.5	-6.51	-176	-2.16	-41.3
Depreciation
Amortisation
Non-Cash Items	3.81	-10.5	149	-43.2	-20.4
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-2.64	1.94	-14.4	-9.07	13.5
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-10.4	-13.6	-38.2	-45.6	-36
Capital Expenditures	-15.7	-15.9	-56.7	-49.6	-21
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0.581	-2.47	-97.1	-62.8	120
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-15.1	-18.4	-154	-112	99.4
Financing Cash Flow Items	—	-11.8	—	—	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	55.3	400	-3.75	40.2	-1.1
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	29.8	368	-198	-113	62.7